Outlook Therapeutics Inc Quick Ratio (OTLK) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
OTLK's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth
Outlook Therapeutics Inc 's Cash & cash equivalent grew by 45.09 % in the Q3 2026 sequentially, while Current Liabilities decreased, this led to improvement in Outlook Therapeutics Inc 's Quick Ratio to 0.39, Quick Ratio remained below Outlook Therapeutics Inc average.
Within Biotechnology & Pharmaceuticals industry 129 other companies have achieved higher Quick Ratio than Outlook Therapeutics Inc in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 3439, from total ranking in the second quarter 2026 at 4322.
Outlook Therapeutics Secures $5.0 Million in Private Placement and Holds Potential for Additional $8 Million Investment Outlook Therapeutics, Inc. (Nasdaq: OTLK), a leading biopharmaceutical company dedicated to developing an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the United States and the European Union, recently announced the successful completion of its private placement offering. The company closed the private placement with Syntone Ventures, LLC, an existing stockholder, generating approximately $5.0 million in upfront gross proceeds. This capital infusion will bolster the company s ongoing efforts to achieve regulatory approval for its revolutionary treatment. The private placement involved the issuance and sale of shares of Outlook Therapeutics common stock, along with accompanying warrants. This strategic move will significantly enhance the company s financial position and provide substantial support for its clinical trials, product development, and regulatory activities. The $5.0 million secured through the private placement will be instrumental in advancing the development and commercialization of Outlook Therapeutics bevacizumab formulation.
Iselin-based biopharmaceutical company, Outlook Therapeutics, has successfully concluded its private placement, securing upfront gross proceeds of approximately $60 million. In addition, the company has the potential to further bolster its financial position with up to $99 million upon the exercise of warrants issued in the private placement. This funding will support Outlook Therapeutics pursuit of the first approval for an ophthalmic formulation of bevacizumab, dedicated to treating retinal diseases in both the US and the EU.
Outlook Therapeutics, Inc. (Nasdaq: OTLK) recently closed its private placement, generating significant financial support for its pioneering efforts in retinal disease treatment. The private placement has brought in around $60 million in upfront gross proceeds from the issuance and sale of the company s common stock, along with accompanying warrants. This sum does not include placement agent fees and offering expenses.
On the trailing twelve months basis OTLK Cash & cash equivalent grew by 26.3 % in Q3 2026 year on year, while Current Liabilities plummeted to $29 millions, this led to increase in in Outlook Therapeutics Inc 's Quick Ratio to 0.22, Quick Ratio remained below OTLK average. Quick Ratio is the average cumulative value over the last four quarters.
Among companies operating within Biotechnology & Pharmaceuticals industry 143 other companies have achieved higher Quick Ratio than Outlook Therapeutics Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending second quarter 2026 at 3184.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
